In prostate cancer, GR activation inhibited tumor angiogenesis [13] and reduced proliferation in primary hormone-sensitive prostate cancer cell lines [14], while GR signaling facilitated resistance to anti-androgen therapies in advanced prostate cancer [15,16]. Here, NR3C1 is linked to neoplasm.